A potential drawback to the use of low-molecular-weight small-molecule PSMA inhibitors in the treatment of prostate cancer, relates to their rapid redistribution in the body and localization to the parotid, salivary, and lacrimal glands as well as to the kidney, leading to dose-limiting toxicities. This evidence concerns the gene FOLH1 and prostate carcinoma.